



## MicroRNA in Solid Tumor and Hematological Diseases

Guest Editor:

**Dr. Francesca Lovat**

Comprehensive Cancer Center,  
Ohio State University, Columbus,  
OH 43210, USA

Deadline for manuscript  
submissions:

**closed (28 February 2021)**

### Message from the Guest Editor

Dear Colleagues,

MicroRNAs (miRNAs), short non-coding RNA, are involved in physiologic and pathologic processes. miRNAs play a key role in cancer pathogenesis by inhibiting gene expression at the post-transcriptional level. Moreover, miRNAs are differentially expressed in tumors compared to normal human tissues and they can be divided into oncomiRNAs and tumor suppressor miRNAs, although some miRNAs can act both roles depending on the cellular context. As a potential therapeutic approach for cancer, extensive studies have demonstrated how to deregulate the small non-coding transcriptome, whether down-regulating the expression of oncogenic miRNAs or overexpressing tumor-suppressive miRNAs. Therefore, the accurate analysis of miRNAs expression from cancer patients might be a useful tool to develop personalized medicine in the future.

This Special Issue will focus on the role of miRNAs in controlling pivotal biological mechanisms that lead to oncogenic transformation and tumor formation, growth, and dissemination, as well as their diagnostic and prognostic significance in different cancer subtypes.

Dr. Francesca Lovat

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)